Cited by 29Mesenchymal stem cell researchLiver Disease and TransplantationLiver physiology and pathology

Mesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials

Open access
Huang, Wei-Chen, Li, Yuan-Chi, Chen, Pin-Xuan, Ma, Kevin Sheng-Kai, Wang, Li-Tzu·2025·Stem Cell Research & Therapy

Abstract

Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials. MSCs derived from bone marrow and umbilical cord have shown remarkable promise in reversing liver damage, improving liver function, and providing hope for patients who do not respond to conventional therapies. When administered through hepatic, portal, or peripheral veins, MSCs have significantly improved liver histology, reduced fibrosis, and restored functional capacity. Furthermore, MSC-derived materials, such as extracellular vesicles and exosomes, are emerging as cutting-edge tools for treating liver failure and mitigating post-transplant complications. While autologous MSC-derived hepatocytes hold promise for non-fatal cirrhosis, allogeneic MSCs are being applied in more severe conditions, including liver failure and transplantation cases. Despite these promising early outcomes, larger trials and long-term studies are essential to fully harness MSCs as a transformative, off-the-shelf alternative to liver transplantation, heralding a new era in regenerative liver therapies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-024-04127-y

Cites

111 of 111 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When exposed to an inflammatory milieu, MSCs can orchestrate local and systemic innate and adaptive immune responses through direct cell contact or remotely secreting immune modulators including TGF-β1, HGF, PGE2, IDO, NO, HO-1, IL-6, IL-10, IL-11, IL-25, IL-1Rα, PD-L1, PD-L2, TSG6, HNF4α, HLA-G5, and galectin.

    “When exposed to an inflammatory milieu, MSCs can orchestrate local and systemic innate and adaptive immune responses through direct cell contact or remotely secreting immune modulators, including but not limited to TGF-β1, HGF, PGE2, indoleamine 2,3-dioxygenase (IDO), NO, HO-1, IL-6, IL-10, IL-11, IL-25, interleukin 1 receptor antagonist (IL-1Rα), programmed death-ligand (PD-L) 1 (B7-H1), PD-L2 (B”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [134]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Huang, W.-C., Li, Y.-C., Chen, P.-X., Ma, K. S.-K., & Wang, L.-T.
Affiliations
  • Tri-Service General Hospital (TW)
  • Taipei Medical University (TW)
Corresponding author
Wang, Li-Tzu
Venue
Stem Cell Research & Therapy
Published
2025-01-06
Volume
16
Issue
1
Pages
3-3
ISSN
1757-6512 (ISSN-L)
OpenAlex
W4406089478
Cited by
29
References
111
Citations by year
2026: 14 · 2025: 15
FWCI
4.52
Type
journal article
Language
en
Open access
Locations
  • Stem Cell Research & Therapy (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Science and Technology Council (MOST111-2314-B-016-049, NSTC113-2314-B-038-021)
  • Tri-Service General Hospital (TSGH-D-109077)
  • Taipei Medical University (TMU112-AE1-B08)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
mesenchymal stem cells, liver disease, chronic liver disease, liver cirrhosis, liver failure, stem cell therapy, bone marrow-derived mesenchymal stem cells, human umbilical cord mesenchymal stem cells, liver fibrosis, extracellular vesicles, exosomes, allogeneic mesenchymal stem cells, liver transplantation alternatives, regenerative medicine, immunomodulation, clinical trials
MeSH terms
Animals, Clinical Trials as Topic, Humans, Liver Diseases, Hepatocytes, Mesenchymal Stem Cell Transplantation, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review